Novavax rises after raising 2026 revenue outlook
+0.52% to $7.74 from $7.70
What moved NVAX
- Second-quarter revenue of $57 million beat estimates by about $3.7 million, with a net loss of $0.32 per share narrower than the $0.38 loss expected.
- Novavax raised its full-year 2026 revenue guidance to $235 million-$275 million from a prior $230 million-$270 million range.
- Product sales rose about 76% to $19 million, driven by stronger demand for its Matrix-M adjuvant and higher sales to licensing partners.
Sources: MarketScreener · BioSpace